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Abstract
Background: Head and Neck Cancer (HNC) survivors are at increased risk of developing a second primary cancer
(SPC). Along with the environmental risk factors, genetic factors have been associated with a potential increased
susceptibility to SPC development. We aim to identify the Single Nucleotide Polymorphisms (SNPs) that contribute
to SPC development among HNC survivors through a systematic review and meta-analysis.
Methods: We searched PubMed, Scopus and ISI Web of Science for eligible studies published in English until
January 31st, 2020. We included studies reporting primary data that evaluated the association between SNPs and
SPC risk in HNC patients. Data were pooled in a random-effect meta-analyses, when at least two studies on the
same SNP evaluated the same genotype model. Heterogeneity was assessed using the χ2-based Q-statistics and the
I2 statistics. Quality of the included studies was assessed using the Q-Genie tool.
Results: Twenty-one studies, of moderate to good quality, were included in the systematic review. Fifty-one genes
were reported across the included studies to have significant associations with an increased SPC risk. Overall, 81 out
of 122 investigated SNPs were significantly associated with the SPC risk. Seven studies were included in the meta-
analysis, which showed five SNPs associated with an increased risk of SPC: p21C70T, CT + TT (HR = 1.76; 95% CI:
1.28–2.43); FASLG -844C > T, CT + TT (HR = 1.82; 95% CI: 1.35–2.46), P21 C98A, CA + AA (HR = 1.75; 95% CI: 1.28–2.38);
FAS -670A > G (HR = 1.84; 95% CI: 1.28–2.66) and GST-M1, Null genotype (HR = 1.54; 95% CI: 1.13–2.10).
Conclusions: The identified SNPs in our systematic review and meta-analysis might serve as potential markers for
identification of patients at high risk of developing SPC after primary HNC.
PROSPERO Registration Number: CRD42019135612.
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Background
Head and neck cancer (HNC) is a group of cancers that
occur in oral cavity, pharynx and larynx, it is the sixth
most common cancer, with approximately 650.000 new
cases and 300.000 deaths annually [1]. Although the
overall survival-rate after the primary HNC have in-
creased [2] due to an improved diagnosis and thera-
peutic approaches, the incidence of second primary
cancer (SPC) remains one of the main long-term causes
of mortality [3, 4]. It is estimated that approximately
15–25% of HNC patients develop SPCs within five years
of initial diagnosis [5, 6]. The main risk factors associ-
ated with the development of SPC in HNC survivors in-
clude environmental factors such as tobacco use, alcohol
consumption, and human papillomavirus infection, as
well as genetic factors [1]. With advancements in genet-
ics and genomics, especially with DNA sequencing, gen-
etic factors have become increasingly studied for their
potential role in the development of HNC [7]. The af-
fected genes are responsible for normal cell growth,
DNA-repair, cell-cycle control, programmed cell death
(apoptosis), cell differentiation and oxidative stress [8].
Genome wide association studies (GWAS) have already
demonstrated important associations between several
genetic abnormalities and HNC carcinogenesis [9, 10].
Although single nucleotide polymorphisms (SNPs) have
been widely studied for a potential increased susceptibility
to HNC development [11, 12], there is still no consistent
evidence about the effect of SNPs among HNC patients
into developing SPCs. Identification of genes and genetic
markers associated with poor survival after HNC may
distinguish patients with increased SPC risk, facilitating
surveillance and enabling targeted interventions while re-
ducing mortality [13]. Therefore, it is important to identify
pathways of carcinogenesis that might serve as potential
markers for identification of patients at high risk of
developing SPC after primary HNC. To address this issue,
we aimed to review and analyze the available literature
and identify the SNPs that contribute to SPC development
among HNC patients and to provide quantitative assess-
ment of the associations between SNPs and SPC risk.
Methods
This systematic review was conducted and reported based
on the Preferred Reporting Items for Systematic Reviews
and Meta-analysis Protocol (PRISMA-P) checklist [14]
(Additional file 1). The protocol of this research was regis-
tered on International prospective register of systematic
reviews database (PROSPERO) with the registration num-
ber CRD42019135612.
Eligibility criteria
Studies were considered eligible for inclusion if they
evaluated the association between SNPs and SPC risk in
HNC patients, and if they provided the effect measures
with the corresponding 95% confidence interval (CI).
Studies reporting primary data were included. There
were no restrictions on primary HNC stage or treatment
status. According to Warren and Gates criteria, a SPC is
defined as a second cancer that developed after a
primary cancer, that is of non-squamous cell origin, or
which has developed in a different location other than
the primary cancer. If the second cancer is of squamous
cell origin and has developed in the same region as the
primary cancer, it is only coded as an SPC if more than
60months had passed since the primary cancer diagno-
sis [15]. Therefore, outcomes such as recurrences, me-
tastases or multiple primary cancers were excluded from
this review. Studies were also excluded if they reported
genetic alterations such as microsatellite instability or
genetic variants over-expression. Editorials, comments,
conference papers, narrative reviews, case reports, case
series and descriptive cross-sectional studies were also
excluded.
Search strategy
Two researchers [IH; VV] systematically searched PubMed,
Scopus and ISI Web of Science online databases for eligible
studies published in English from inception until January
31st, 2020. The following search query was used in
PubMed: (((Head and Neck) OR pharynx OR pharyngeal
OR oropharynx OR oropharyngeal OR hypopharynx OR
hypopharyngeal OR nasopharynx OR nasopharyngeal OR
larynx OR laryngeal OR (oral cavity) OR (upper aerodiges-
tive tract) OR UADT) AND (tumor OR neoplasm* OR can-
cer OR malignanc* OR carcinoma)) AND ((second primary)
OR SPC) AND ((genetic AND (characterization OR
alterations OR variant OR polymorphism)) OR gene OR
microRNA OR SNP OR (single nucleotide polymorphisms)
OR polymorphism* OR biomarker*).
Other two databases were searched using the appropri-
ately modified PubMed search query (details are available
upon request).
Subsequently, the reference lists of the included studies
were manually searched for additional relevant publica-
tions. In the second step, aiming to understand whether
GWASs identified any genetic loci associated with the risk
of SPC in HNC patients, we also explored the following
GWAS databases: GWAS Central National Human
Genome Research Institute (NHGRI GWAS Catalog) [16],
The database of Genotypes and Phenotypes (dbGaP) [17];
The GRASP: Genome-Wide Repository of Associations
Between SNPs and Phenotypes, and The genome wide
association database (GWAS DB) [18].
Study selection
Identified studies from all databases were uploaded to
Mendeley Reference Manager and duplicate articles were
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removed. Two independent researchers [IH; VV] per-
formed the first screening based on titles and abstracts.
In the second stage of screening, studies with full texts
available were carefully reviewed. Studies that met the
eligibility criteria were selected for inclusion. The PRIS
MA flow chart was created, reporting all the steps of
search strategy and study selection: total number of
studies retrieved, number of excluded studies during
title/abstract screening, and number of studies excluded
during full-text assessments, along with reasons of ex-
clusion. Disagreements were resolved through discussion
with the third researcher [RP] until the consensus was
reached.
Data extraction
From each of the included studies, two researchers [IH;
VV] independently extracted the following data: first au-
thor, year of publication, study design and setting, study
size, patients' ethnicity, primary HNC site, follow-up
period, number of patients with SPC, SPC site(s), genes,
chromosomes, SNPs, measure of association and corre-
sponding genetic model. Researchers double-checked the
extracted data and few subsequent discrepancies were re-
solved through discussion and in consultation with another
researcher [RP].
Quality assessment
Two researchers [IH; VV] independently assessed quality
of the included studies using the Q-Genie tool, which
was specifically designed for the evaluation of genetic
association studies [19]. This tool contains 11 items,
assessing: rationale for conducting the study, selection
and definition of outcome of interest, selection and com-
parability of comparison groups, technical and non-
technical classification of the exposure, other source of
bias, appropriateness of sample size and power, descrip-
tion of the analyses and statistical methods used, testing
of assumptions and appropriateness of inferences drawn
from results. Each item is rated on a 7-point scale: “1
point – poor”; “2 and 3 points - good”; “4, 5 and 6
points - very good” and “7 - excellent”. For studies with
control group, the overall quality of studies is catego-
rized as the following: “poor quality” if score ≤ 35; “mod-
erate quality” if score > 35 and ≤ 45; and a “good quality”
if score > 45. For studies without control groups, values
for each of the categories listed are ≤ 32; > 32 and ≤ 40;
and > 40, respectively. Any disagreement was solved
through discussion with the third researcher [RP].
Data synthesis and analysis
The main findings were reported in a tabular synthesis,
separately for each SNP, and the qualitative synthesis
reported possible associations of each SNP with the SPC
risk. Meta-analysis was performed considering different
study designs, and the SNPs studied reported in each study.
When at least two studies on the same SNP were available
and evaluated the same genotype model, the data were
pooled in a random-effect meta-analyses [20]. Effect size
were expressed as hazard ratios (HR) or odds ratios (OR)
with the corresponding 95% confidence intervals (CI), as
appropriate. We stratified the analyses according to the site
of SPC. The heterogeneity between studies was assessed
using the χ2-based Q-statistics and the I2 statistics [21].
The heterogeneity was considered low if the I2 value was <
25%. P-values of less than 0.05 were considered statistically
significant. To assess the presence of publication bias
(where appropriate), we conducted Egger’s asymmetry test
(level of significance p < 0.05) for the SNPs with at
least three pooled studies [22]. Statistical analyses were per-
formed using the Stata software package version 13 (Stata-
Corp. College Station. Texas).
Results
Search results
The initial search of PubMed, ISI Web of Science and
Scopus databases identified a total number of 3053
articles. After removing the duplicates, 2635 articles
were screened by title and abstract. One hundred forty-
seven full-text articles were evaluated, of which twenty-
one articles met the inclusion criteria. No additional
studies were included after checking the reference lists
of the included articles. The entire process of the litera-
ture search and study selection is reported in details in
the PRISMA Flowchart in Fig. 1. From the search of
GWAS databases, we did not find any GWAS on genetic
loci associated with a risk of SPC in HNC patients.
Characteristics of the studies
Characteristics of the twenty-one included studies
[23–43] are reported in Table 1. Sixteen studies were
of cohort study design and five were case-control
studies, published from 2005 to 2019. Eighteen studies
were conducted in the USA, seventeen of which re-
trieved patients from the same randomized placebo-
controlled trial [44], investigating different genes and
SNPs. The remaining three studies were performed in
Canada, United Kingdom and Italy. The number of HNC
patients included in the cohort studies varied from 215 to
1529. The majority of patients were male. Median follow-
up time varied from 2.1 to 5.21 years. Studies conducted
in the USA reported data on the ethnicity where most pa-
tients were of non-Hispanic white ethnicity. Regarding
primary HNC site, twenty studies evaluated all HNC sites
(oral cavity, larynx, pharynx), whereas the study by Gal
et al. [28] investigated only oral cavity site. As for the SPC
site, twelve studies reported data on tobacco-related SPC
(esophagus, lung or bladder) and on non-tobacco-related
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SPC (prostate, thyroid or colon); while nine remaining
studies did not report site-specific data.
Fifty-one genes (p53, GST, p73, p21, ERCC5, MDM4,
MMP21, GSTM5, BCCIP, TNKS1BP1, RAD54L, CAD9,
CDK8, FAS, JAK2, P27, SLC31A1, DNMT3B, MDM2,
P14ARF, MMP3, RXRA, TSC1, CDC25C, FASL, FLT3,
CASP3, KRAS, RGS5, BCL2L2, GPX1, MKI67, MNAT1,
RNASEN, IGF1R, PDGFB, TNFRSF10B, CDK6, AXIN,
XPO5, CAT, GLI2, CFTR, RGS11, GSTM4, IL1R1,
NR1I2, NHEJ1, SMC1B, SSTR2, RNF2) were reported to
have significant associations with the SPC risk. Overall,
the most investigated genes were GST gene family (five
studies), p53 (four studies), p73 (three studies), and by 2
studies each of the following genes p21, FAS and FASL,
and XPD (ERCC2). A total of 122 different SNPs were
explored, of which 81 SNPs were significantly associated
with the SPC risk, in particular with an increased risk.
Data for the investigated SNPs are reported separately,
according to the study design. The SNPs investigated in
cohort studies are reported in Table 2, whereas the SNPs
evaluated in case-control in case-control studies are re-
ported in Table 3. The GST gene family polymorphisms
explored were GST-M1, GST-T1 and GST-P1. GST-
M1 null genotype was associated with an increased risk
Fig. 1 PRISMA Flow chart of screening and selection process of studies included in systematic review
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for any SPC (HR = 1.99; 95% CI: 1.11–3.56) and for
tobacco-related SPCs (HR = 2.16; 95% CI: 1.01–4.62),
whereas the GST-T1 null genotype demonstrated
statistically non-significant protective effects for the SPC
development (HR = 0.59; 95% CI: 0.25–1.41). Patients
with both GST non null genotypes were 0.52 times less
likely (95% CI: 0.28–0.96) to develop a SPC compared to
participants who had the GST-M1 null and GST-T1 non
null genotypes. Patients with the GSTP1 gene Ile105Val
polymorphism had a 1.7-fold elevated risk for developing
SPC compared to patients with the wild-type genotype
(HR = 1.7; 95% CI: 1.1–2.5). The combined risk of
GSTP1 gene 105 and GSTP1 114 polymorphisms, in-
creased SPC risk, suggesting that two polymorphisms
may have a joint effect on the risk of SPC development
[40].
The p53 gene rs1042522 polymorphism was explored
by four studies, of which three reported significant asso-
ciation for increased SPC risk. Patients with p53 WP+
PP genotype [27] and patients with p53 72 Arg/Pro
genotype [23] had an increased SPC risk. Patients with
the combined p53 variant (Arg/Pro + Pro/Pro) geno-
types, and patients with the combined polymorphisms
p53 codon 72 and p73 G4C14-to-A4T14 [27], had a sig-
nificantly increased SPC risk.
The p21 gene C98A and C70T polymorphisms geno-
types were distributed significantly different between pa-
tients who developed SPC and those who did not. Patients
with p21 98 CA/AA and p21 70 CT/TT variant genotypes
had a significantly increased SPC risk [30, 43]. The com-
bined effect of both p21 polymorphisms together on SPC
risk, showed that patients with either variant allele (p21 98
A or p21 70 T) had a 2-fold increased SPC risk compared
with patients with the combined p21 98 CC and p21 70
CC wild-type genotypes [30, 43].
The FAS gene polymorphism showed that the SPC risk
differed according to the index HNC site. Patients with
index OPC and FASL 844 CT/TT genotype had
Fig. 2 Forest plot on associations of seven Single Nucleotide Polymorphisms with Second primary cancer risk in HNC patients
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significantly increased SPC risk (aHR, 2.7; 95% CI: 1.2–
6.0, p = 0.032) while index non-OPC patients with
FAS670 AG/GG and FasL844 CT/TT genotypes had
significantly increased risk of SPC (aHR, 2.4 and 1.7;
95% CI, 1.1–5.1 and 1.0–3.0; and p = 0.043 and 0.049, re-
spectively). Patients carrying more FAS/FASL variants
had significantly increased risk of SPC among index non-
OPC patients [29]. Overall, a non-site-specific increased
SPC risk in patients with FAS -670 AA and the FASLG
-844 CC genotypes was also reported by Lei D et al. [25],
which further showed an increased SPC risk, in a dose-
response manner, with the combined risk genotypes, of
four polymorphisms on the SPC risk.
The XPD gene Lys751Gln polymorphism carriers had
a non-significant reduced SPC risk [28, 39]. The study
by Zafereo et al. [39] did not find a significant SPC risk
also in stratified analysis by SPC type. However, when
they combined XPD gene Lys751Gln polymorphism with
other six SNPs of the core genes in the nucleotide exci-
sion repair (NER), in a dominant model there was a
trend for increased SPC risk with increasing number of
risk genotypes [39].
Quality assessment
Results of the quality assessment of the included studies
are reported in Additional file 2. Among fifteen studies
without group control, only the study by Wang et al.
[24], had moderate quality, while the others were of
good quality. The study by Wang et al. [24] had moder-
ate quality due to the scarcity in disclosure of potential
sources of bias and for not testing of assumption and in-
ferences for genetic analyses. Six studies with group con-
trol were of moderate quality, mostly because of the
poor non-technical classification of the exposure, and
for not testing of assumption and inferences for genetic
analyses.
Meta-analysis
Seven cohort studies, that reported the same genotype of
the same SNP in at least two studies, were included in the
meta-analysis. The included SNPs and their genotypes
were p21 C70T, CT + TT genotype; FASLG -844C > T,
CT +TT genotype; P21 C98A, CA +AA genotype; FAS
gene -670A >G; GST-M1, Null genotype; GST-T1, Null
genotype; and XPD Lys 751 Gln, Gln/Gln genotype.
All the studies included in the meta-analysis adjusted
the estimates for age, sex, smoking and alcohol [25, 29,
30, 34, 39, 40, 43]. Some of the studies adjusted also for
other variables: ethnicity [25, 29, 30, 39, 40, 43], treat-
ment [29, 34] and primary HNC site [28, 29, 34].
The associations between SNPs and SPC risk, stratified
by SNP, are shown in the Forest plot in Fig. 2. Pooled
analysis revealed five SNPs with a statistically significant
increased SPC risk: p21C70T, CT + TT genotype (HR =
1.76; 95% CI: 1.28–2.43; I2 = 0.0%); FASLG -844C > T,
CT + TT genotype (HR = 1.82; 95% CI: 1.35–2.46; I2 =
0.0%); P21 C98A, CA + AA genotype variant (HR = 1.75;
95% CI: 1.28–2.38; I2 = 0.0%); FAS -670A > G (HR = 1.84;
95%CI: 1.28–2.66; I2 = 0.0%) and GST-M1, Null geno-
type variant (HR = 1.54; 95% CI: 1.13–2.10; I2 = 2.0%). A
non-significant decreased SPC risk was associated with
GST-T1, Null genotype variant (HR = 0.90; 95% CI:
0.51–1.59; I2 = 32.8%); and XPD Lys751Gln, Gln/Gln
genotype variant (HR = 0.98; 95% CI: 0.62–1.55; I2 =
0.0%). In each of the pooled analysis there was no het-
erogeneity between studies. The Egger test demonstrated
no statistical evidence of publication bias for funnel plot
FASLG -844C>T (p= 0.363) and FAS -670A>G (p= 0.24).
Stratified analysis according to the SPC site was pos-
sible for three SNPs: XPD Lys 751 Gln/Gln; GST-T1
Null; and GST-M1 Null. There was a non-significant de-
creased risk for HNC squamous cell carcinoma SPC in
patients with XPD Lys751Gln, Gln/Gln genotype (HR =
0.46; 95% CI: 0.17–1.25; I2 = 25.1%). For tobacco-related
SPC, the risk was decreased in GST-T1 Null carriers
(HR = 0.83; 95% CI:0.48–1.43; I2 = 0.0%). and increased
in GST-M1 Null carriers (HR = 1.53; 95% CI:0.96–2.44;
I2 = 18.4%), although the associations did not reach the
level of significance (Additional file 3).
Discussion
This systematic review on genetic associations of SPC
development after primary HNC included twenty-one
studies and reported fifty-one genes with a significantly
increased SPC risk. These genes were involved in differ-
ent carcinogenesis pathways, including detoxification,
DNA repair, apoptosis or cell cycle regulation, develop-
mental pathway and cell adhesion. A total of 122 SNPs
were investigated, of which eighty-one SNPs were sig-
nificantly associated with an increased risk of SPC
among HNC patients. Five SNPs (p21C70T, FASLG
-844C > T, P21 C98A GST-M1 and GST-T1) were sig-
nificantly associated with an increased SPC risk in our
meta-analysis. Genes of these five SNPs are involved in
different pathways of carcinogenesis, such as apoptosis
process or cell cycle regulation, DNA repair mechanism
and carcinogen detoxification processes [45, 46].
The p21 gene C98A polymorphism, that resulted with a
significantly increased SPC risk in our meta-analysis,
causes a non-synonymous serine-to-arginine substitution
at codon 31 and has been reported to contribute to gen-
etic susceptibility to cancer, including HNC [47], endo-
metrial [48] and breast cancer [49]. The influence of P21
gene polymorphisms in cancer risk, including HNC, has
been reported previously [47, 50, 51].
FAS -670A > G and FASLG -844 T/C polymorphisms
have been previously associated with an increased risk of
HNC [52], gynecological cancer [53] and esophageal
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squamous cell cancer [54], whereas FAS -670A > G has
been also associated with an increased risk of recurrence
and death in epithelial ovarian cancer patients [53]. FAS
and FASLG genes have a crucial role in apoptosis pro-
cesses and their polymorphisms have been reported to
affect the risk of cancer, including SPCs [55]. These
polymorphisms modified the risk of SPCs differently for
index OPC from non-OPC patients [29], suggesting that
primary cancer site may contribute to the association of
apoptosis and SPC risk. The significant associations of
FAS/FASL variant genotypes with the increased SPC risk
in those HNC patients ever smokers or ever drinkers
might suggest that genetic factors, within the context of
previous or continued exposure to smoking and alcohol
consumption may affect the risk of SPC development [29].
GST-M1 null genotypes and GST-M1 null genotypes
have been previously associated with an increased risk of
HNC [56] and lung cancer [57], respectively. GSTs
genes, having a crucial role in carcinogen detoxification,
have been associated with an increased risk of HNC,
skin, breast, lung and bladder [58]. The XPD Gln751Lys
polymorphism had no significant association with a re-
duced SPC risk from our meta-analysis, despite the fact
that XPD gene, acting as a key DNA repair protein in
the NER pathway, is involved in cancer pathogenesis.
Despite the abundant evidence about the SNPs associ-
ated with the risk of primary HNC and the biological
pathways, their genetic associations with the SPC risk
and the carcinogenesis pathways, in particular in HNC
patients, are still not sufficiently explored, and none
GWAS has addressed this susceptibility. To our know-
ledge, there were not publicly available data from
GWAS on the genetic associations of the seven SNP in-
cluded in our meta-analysis with the development of any
SPC.
There are some limitations in our study that should be
pointed out. We included only studies published in Eng-
lish, therefore some studies in other languages or cur-
rently unpublished data might have been missed,
indicating the possibility of publication bias. The majority
of studies included in the systematic review investigated
different SNPs in the same cohort of patients, thus the
SNPs included in the meta-analysis were identified by only
two primary studies. The stratified analysis according to
smoking, alcohol status, treatment, or primary HNC site,
were conducted in only few studies, that were not the ones
included in our meta-analysis. The estimates of associ-
ation may be biased due to the lack of this information.
Although data were pooled in the meta-analysis ac-
cording to the genotype variant, it was not possible
to identify the best genetic model for each SNP, be-
cause not all the studies reported genotype data that
could enable us to calculate the estimates according
to a genetic model. The results may vary depending
on the genetic model used in statistical significance,
however still remains the uncertainty on the best gen-
etic model for the association of interest.
Despite these limitations, we addressed the potential
publication bias by exploring GWAS publicly available
websites. Except one study of moderate quality, the
other studies included in the systematic review, and also
in the meta-analysis were of good quality. To our know-
ledge, this is the first systematic review and meta-analysis
to summarize the studies on the genetic associations of
SPC development after primary HNC. The large number
of genes included in this systematic review, could serve as
an import guide to the researchers to choose the genes
that can be studied further in the future. However, the re-
ported associations, in particular for the polymorphisms
not included in the meta-analysis, need to be confirmed in
future studies.
Studies included in the systematic review reported
small number of HNC patients developing SPC due to
the insufficient follow-up times. Therefore, GWASs, lar-
ger and well-designed studies with longer follow-up
time, and further studies pathway-oriented on biological
functions of the polymorphisms, are needed in order to
improve our knowledge of the genetic associations that
influence the SPC occurrence after a primary HNC. Fur-
thermore, the combined effect of a panel of polymor-
phisms that act in the same carcinogen metabolizing
pathway support the notion that SPC development after a
primary HNC is a polygenic process. The effects of associ-
ations of these polymorphisms with the SPC risk might be
amplified, suggesting that their further exploration may
provide higher predictive estimates of association [36, 40].
In HNC patients, genetic testing for these SNPs, with evi-
dences on clinical validity and utility, might be helpful for
the identification of high-risk patients for developing a
SPC, leading to personalized approaches and an early
diagnosis of SPC. Moreover, considering that both, HNC
and SPC result from complex interactions of genetic vari-
ants and environmental factors, further studies should
focus on these interactions in SPC development. Future
studies should also investigate the influence of risk factors,
such as tobacco smoking, alcohol consumption or HPV
status, and different treatment modalities in overall and
site-specific SPC risk.
Conclusions
The polymorphisms identified and summarized in this
study may serve as a potential therapeutic targets or
markers for genetic susceptibility to SPC after an index
HNC, that may further enhance the identification of
high-risk groups of HNC patients, aiming to provide a
personalized treatment for an improved prognosis and a
better quality of life.
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